Pilot Study of Fosamax in Spinal Cord Injury

Stopped early · Not applicable · Has a placebo group

Conditions studied: Spinal Cord Injury, Osteoporosis

In brief

Study is designed to evaluate the efficacy of oral fosamax in prevention on osteoporosis in acute spinal cord injury. Efficacy will be measured by a duel energy X-Ray absorptiometry (DEXA) scan every 6 months. Patients will complete 3 visits, screening, 6 months, 12 months and be required to take oral fosamax versus placebo weekly.

Key facts

Study ID

NCT01131884

Run by

University of Rochester

People needed

1

Starts

2010-06-01

Expected to finish

2012-12-01

Last updated by the study team

2016-01-29

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• American Spinal Cord Injury Association (ASIA) A or American Spinal Cord Injury Association (ASIA) B Spinal Cord Injury

You may not qualify if…

• History of hypersensitivity to alendronate or other bisphosphonates
• esophageal abnormality
• inability to sit/stand upright for 30 minutes
• creatinine clearance less than 35 milliliters/minute
• hypothyroidism
• malignancy
• pregnancy
• prolonged steroid use

Where it is running

• University of Rochester Physical Medicine and Rehabilitation — Rochester, New York, United States
• University of Rochester — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.